These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 10416269)
1. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice. Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269 [TBL] [Abstract][Full Text] [Related]
2. Statistical analysis of skin tumor data from Tg.AC mouse bioassays. Dunson DB; Haseman JK; van Birgelen AP; Stasiewicz S; Tennant RW Toxicol Sci; 2000 Jun; 55(2):293-302. PubMed ID: 10828260 [TBL] [Abstract][Full Text] [Related]
3. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: evaluation of husbandry and housing factors. Holden HE; Stoll RE; Spalding JW; Tennant RW J Appl Toxicol; 1998; 18(1):19-24. PubMed ID: 9526830 [TBL] [Abstract][Full Text] [Related]
4. Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. Spalding JW; Momma J; Elwell MR; Tennant RW Carcinogenesis; 1993 Jul; 14(7):1335-41. PubMed ID: 8330346 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions. Sistare FD; Thompson KL; Honchel R; DeGeorge J Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901 [TBL] [Abstract][Full Text] [Related]
14. Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice. Nylander-French LA; French JE Toxicol Pathol; 1998; 26(4):476-83. PubMed ID: 9715506 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II. Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852 [TBL] [Abstract][Full Text] [Related]
16. The Tg rasH2 mouse in cancer hazard identification. Morton D; Alden CL; Roth AJ; Usui T Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467 [TBL] [Abstract][Full Text] [Related]
17. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Thompson KL; Rosenzweig BA; Sistare FD Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Tennant RW; Spalding J; French JE Mutat Res; 1996 Sep; 365(1-3):119-27. PubMed ID: 8898993 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of dichloroacetic acid for carcinogenicity in genetically modified Tg.AC hemizygous and p53 haploinsufficient mice. Kissling GE; Malarkey DE; Vallant MK; Johnson JD; Hejtmancik MR; Herbert RA; Boorman GA Toxicol Sci; 2009 Jan; 107(1):19-26. PubMed ID: 18974089 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components. Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]